SPN-812 not checked

Supernus Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
12 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“100mg SPN-812 will be administered once daily and compared to Placebo”In the company’s words, NCT04781140 on ClinicalTrials.gov
Tested for
Attention-Deficit/Hyperactivity Disorder (2 trials)
Main trialPhase 4
“This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.”In the company’s words, NCT04781140 on ClinicalTrials.gov
Other names
Viloxazine extended-release capsules · Low Dose · Low-Medium Dose · Medium-High Dose · High Dose

Other drugs for Attention-Deficit/Hyperactivity Disorder

All 5 drugs for Attention-Deficit/Hyperactivity Disorder

Coming up2

Changes1

Last 90 days

Trials12

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Jan 2028 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Phase 3Active, not recruiting Dec 2026 Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)
Phase 4Completed 23 May 2023 Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD
Phase 4Completed 20 Sep 2023 Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women
Phase 4Completed 3 Dec 2024 Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Phase 3Completed 12 Sep 2018 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
Phase 3Completed 17 Oct 2018 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
Phase 3Completed 17 Oct 2018 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
Phase 3Completed 14 Feb 2019 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
Phase 3Completed 10 Oct 2020 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Phase 3Completed 26 Jul 2022 Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Phase 2Completed 25 Jul 2016 Efficacy and Safety of SPN-812 (Viloxazine Extended-release Capsule) in Children With ADHD
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SPN-812

Following is part of Solo: you see every change to SPN-812 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in